Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid
| Autor: | R.M. Ponce-Olivera, V.L. Díaz-Molina, A. Tirado-Sánchez |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
Male medicine.medical_specialty Pemphigoid medicine.medical_treatment Immunology Azathioprine Dapsone Pharmacotherapy Adjuvants Immunologic Pemphigoid Bullous medicine Immunology and Allergy Humans skin and connective tissue diseases Aged Retrospective Studies Autoimmune disease integumentary system business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease Dermatology eye diseases Prednisone Drug Therapy Combination Female Bullous pemphigoid business Adjuvant Immunosuppressive Agents medicine.drug |
| Zdroj: | Allergologia et immunopathologia. 40(3) |
| ISSN: | 1578-1267 |
| Popis: | Summary Background Bullous pemphigoid is a chronic, blistering and autoimmune disease, common in old age. The treatment usually includes systemic steroids, however, these cause high morbidity rates, and then different products that function as adjuvants have been tried. At present, there are no studies to determine which adjuvant offers a better efficacy and safety profile. Methods We performed a retrospective study which included the records of patients with bullous pemphigoid, treated either with azathioprine or dapsone. We evaluated the time to achieve complete remission, the time to inhibit disease progression, and the control of pruritus. Results Fifteen records of patients were selected, eight (53%) treated with azathioprine and seven (47%) with dapsone. Complete remission was achieved at week six in both groups. We found no difference in the inhibition of disease progression (p = 0.083). Pruritus was controlled at four weeks of treatment in both treatments. Conclusions Both products are effective as adjuvant in the treatment of bullous pemphigoid, with an acceptable safety profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|